| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | palivizumab (Synagis®) |
| Formulation | 100 mg/ml solution for injection |
| Reference number | 2895 |
| Indication | Prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease: children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season; children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months; children less than 2 years of age and with haemodynamically significant congenital heart disease |
| Company | AbbVie Ltd |
| BNF chapter | Infections |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 23/10/2015 |